A Study of Clinical Efficacy of GnRH Antagonist (Cetrorelix) Single and Multiple Dose Protocol for Controlled Ovarian Hyperstimulation |
Ko, Sang-Hyeon
(Department of Obstetrics and Gynecology, College of Medicine, Chung-Ang University)
Kim, Dong-Ho (Department of Obstetrics and Gynecology, College of Medicine, Chung-Ang University) Bae, Do-Hwan (Department of Obstetrics and Gynecology, College of Medicine, Chung-Ang University) Lee, Sang-Hoon (Department of Obstetrics and Gynecology, College of Medicine, Chung-Ang University) |
1 | Yen SSC. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril 1983; 39: 257-66 DOI |
2 | Lenton EA, Cooke ID, Hooper M, et al. In vitro fertilization in the natural cycle. Bailliere's Clin. Obstet Gynecol 1992; 6: 229-44 DOI ScienceOn |
3 | Judith A F Huirne, Cornelis B Lambalk, Gonadotropin-releasing-hormone-receptor antagonists, The Lancet 2001; 358: 1793-803 |
4 | Ng EH, Ho Pc. Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose. The Journal of Obstetrics and Gynaecology Research 2001; 27; 5: 261-5 |
5 | Karande VC, Jones GS, Veeck L, Muasher SJ. High-dose FSH stimulation at the onset of the menstrual cycle does not suppress the IVF outcome of low-responder patients. Fertil Steril 1990; 53: 486-9 DOI PUBMED |
6 | Van Hooff MHA, Alberda AT, Huisman GJ, et al. Doubling the human menopausal gonadotropin dose in the course of an in vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8: 369-73 DOI |
7 | Albano C, Platteau P, Devroey P. Gonadotropin releasing hormone antagonist: how good is the new hope? Curr Opin Obstet Gynecol 2001; 13:257-62 |
8 | Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 2001; 75; 2: 316-23 |
9 | Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-20 DOI ScienceOn |
10 | Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-91 DOI PUBMED |
11 | Nikolettos N, AI-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. European Journal of Obstetrics & Gynecology and Reproductive Biology 2001; 97: 202-7 DOI ScienceOn |
12 | Diana BL. Applications for GnRH antagonists. Trends Endo Met 2001; 12: 238-40 DOI ScienceOn |
13 | Albano C, Felberbaum R, Smitz J, et al. On behalf of the European Cetrorelix Study Group. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH) -antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 3: 526-31 |
14 | Olivennes F, Frydman R. Friendly IVF: the way of the future? Hum Reprod 1998; 13; 5: 1121-4 |
15 | Devroey P, Mannaerts B, Smitz J, Coelgh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human FSH (Org 32489) combined with various GnRH agonist regimens. Hum Reprod 1994; 9: 1064-9 DOI PUBMED |
16 | Olivennes F, Taieb J, Fanchin R, Selva J, Bouchard P, Frydman R. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 1994;62; 3: 468-76 |
17 | Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized multicenter trial. Hum Reprod 2000; 15: 1490-8 DOI ScienceOn |
18 | Albano C, Riethmuller-Winzen H, Smitz J, Van Steirteghem A, Camus M, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67; 5: 917-22 |
19 | Bronson R. Embryo transfer and multiple gestation. Hum Reprod 1997; 12: 1605-6 DOI ScienceOn |
20 | Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Barous J, Frydman R. the use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13:2411-4 DOI |
21 | Hernandez ER. Embryo implantation: the rubicon for GnRH antagonist. Hum Reprod 2000; 15: 1211-6 DOI ScienceOn |
22 | Claman P, Domingo M, Garner P, et al. Natural cycle in in-vitro fertilization -embryo transfer at the University of Ottawa: an inefficient therapy for tubal infertility. Fertil Steril 1993; 60: 298-302 DOI PUBMED |
23 | Fauser BCJM, Paul D, Yen SSC, Gosden R, Crowley JR WF, Baird DT, et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14; 11:2681-6 |
24 | Smitz J, Van Den Abbeel E, Bollen N, Camus M, Devroey P, Toumaye H, et al. The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in vitro fertilization outcome in normo-ovulatory women. Hum Reprod 1992; 7: 1098-102 DOI PUBMED |
25 | Loumaye E. The control of endogenous secretion of LH by GnRH-a during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 1990;5: 357-76 DOI PUBMED |
26 | Stranger JD, Yovich JL. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92: 385-93 DOI |